Please orient your device to the portrait position to return to the site.

Developed under the direction and sponsorship of Insight Pharmaceuticals LLC

Resistance in Vulvovaginal Candidiasis (VVC)—A Growing Problem

Key Facts About Drug Resistance in VVC

The prevalence of VVC caused by non-albicans Candida has increased tremendously—and these species are less susceptible to fluconazole1
Although Candida albicans is still the most common cause, non-albicans species now account for 30% of vaginal yeast infections. Many are resistant to commonly prescribed antifungal agents, making treatment more challenging.1

Fluconazole resistance often begins in the gut
Oral fluconazole is systemic, and a significant amount of the drug remains in the GI tract. Repeated use reduces the C. albicans population in the gut, allowing resistant non-albicans species to thrive and reach the vagina.2

Fluconazole doses have increased dramatically
The number of fluconazole pills prescribed has more than doubled since 2005, and nearly 60% of patients get more than 1 fluconazole tablet initially.3 These dosing trends may be another indicator of growing resistance.

Optimal treatment for non-albicans VVC is not yet established; CDC Guidelines suggest a non-fluconazole azole for 7-14 days first-line4
The Guidelines also include recommendations for treating VVC in certain populations, including women who are pregnant, diabetic, or immunocompromised.